Gland Pharma Limited — Q2 FY26
Gland Pharma reported a steady Q2 FY26 with consolidated revenue of ₹1,487 crore (+6% YoY) and EBITDA of ₹314 crore (21% margin).
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY26
Synergia positive EBITDA by Q3 FY26
Synergia is committed to delivering positive EBITDA in Q3 FY26, after a lower Q2 due to summer shutdown.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q1 FY26
GLP-1 pen/cartridge capacity expansion to 140M units by March 2026
The new 100M unit line will be ready for commercialization by March-April 2026, with FAT completed by September 2025.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1